| 1.9 0.13 (7.34%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.25  |
1-year : | 4.02 |
| Resists | First : | 2.78 |
Second : | 3.45 |
| Pivot price | 2 |
|||
| Supports | First : | 1.71 | Second : | 1.42 |
| MAs | MA(5) : | 1.79 |
MA(20) : | 2.18 |
| MA(100) : | 2.94 |
MA(250) : | 8.38 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 6.7 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 43.65 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TVRD ] has closed above bottom band by 38.7%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.04 - 2.05 | 2.05 - 2.06 |
| Low: | 1.79 - 1.8 | 1.8 - 1.81 |
| Close: | 1.89 - 1.9 | 1.9 - 1.91 |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Fri, 14 Aug 2026
Tvardi Therapeutics Releases Q2 2026 Financial Results - news.alphastreet.com
Fri, 14 Aug 2026
Tvardi Therapeutics, Inc. 2026: Revenue ($6.46M), EPS ($0.69) — 10-Q Summary - TradingView
Fri, 14 Aug 2026
Tvardi: Q2 Earnings Snapshot - KING5.com
Mon, 10 Aug 2026
Tvardi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVRD - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 26 (%) |
| Held by Institutions | 19.6 (%) |
| Shares Short | 543 (K) |
| Shares Short P.Month | 398 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -68.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -7.04 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|